Failed MyVax Cancer Vaccine Trial Could Be Due To Active Comparator, Genitope Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm remains optimistic about the non-Hodgkin’s lymphoma vaccine due to a statistically significant increase in progression-free survival among MyVax responders.